Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.6989
-$0.0211-2.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.23% | -2.38% | -3.09% | 11.95% | 66.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.26% | -22.04% | -17.91% | 10.89% | 45.66% |
| Operating Income | 27.26% | 22.04% | 17.91% | -10.89% | -45.66% |
| Income Before Tax | 27.42% | 23.81% | 21.26% | -5.50% | -43.61% |
| Income Tax Expenses | -18.78% | 15.38% | -65.89% | 13.20% | 5.45% |
| Earnings from Continuing Operations | 27.42% | 23.79% | 21.29% | -5.51% | -43.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.42% | 23.79% | 21.29% | -5.51% | -43.59% |
| EBIT | 27.26% | 22.04% | 17.91% | -10.89% | -45.66% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 49.80% | 44.75% | 41.23% | 15.27% | -19.29% |
| Normalized Basic EPS | 49.80% | 44.76% | 41.20% | 15.26% | -19.33% |
| EPS Diluted | 49.80% | 44.75% | 41.23% | 15.27% | -19.29% |
| Normalized Diluted EPS | 49.80% | 44.76% | 41.20% | 15.26% | -19.33% |
| Average Basic Shares Outstanding | 46.65% | 39.35% | 35.33% | 30.35% | 26.73% |
| Average Diluted Shares Outstanding | 46.65% | 39.35% | 35.33% | 30.35% | 26.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |